{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,30]],"date-time":"2025-10-30T17:24:48Z","timestamp":1761845088233},"reference-count":52,"publisher":"Informa UK Limited","issue":"1","content-domain":{"domain":["www.tandfonline.com"],"crossmark-restriction":true},"short-container-title":["Expert Review of Hematology"],"published-print":{"date-parts":[[2020,1,2]]},"DOI":"10.1080\/17474086.2020.1697226","type":"journal-article","created":{"date-parts":[[2019,11,23]],"date-time":"2019-11-23T00:20:28Z","timestamp":1574468428000},"page":"31-38","update-policy":"http:\/\/dx.doi.org\/10.1080\/tandf_crossmark_01","source":"Crossref","is-referenced-by-count":7,"title":["Reassessing the role of chemoimmunotherapy in chronic lymphocytic leukemia"],"prefix":"10.1080","volume":"13","author":[{"given":"Yasir","family":"Khan","sequence":"first","affiliation":[{"name":"Division of Hematology and Oncology, University of California Irvine, Irvine, CA, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yung","family":"Lyou","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology and Experimental Therapeutics, City of Hope Comprehensive Cancer Center, Duarte, CA, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Monica","family":"El-Masry","sequence":"additional","affiliation":[{"name":"VA Greater Los Angeles Healthcare System, Los Angeles, CA, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Susan","family":"O\u2019Brien","sequence":"additional","affiliation":[{"name":"Division of Hematology and Oncology, University of California Irvine, Irvine, CA, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"301","published-online":{"date-parts":[[2019,12,10]]},"reference":[{"key":"e_1_3_4_3_1","doi-asserted-by":"publisher","DOI":"10.3322\/caac.21442"},{"key":"e_1_3_4_4_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41571-018-0037-8"},{"key":"e_1_3_4_5_1","article-title":"Chronic lymphocytic leukaemia","author":"Kipps TJ","year":"2017","unstructured":"Kipps TJ, Stevenson FK, Wu CJ, et al. Chronic lymphocytic leukaemia. Nat Rev Dis Primers. 2017 Jan;3:16096.","journal-title":"Nat Rev Dis Primers"},{"key":"e_1_3_4_6_1","doi-asserted-by":"publisher","DOI":"10.3109\/10428194.2013.794267"},{"key":"e_1_3_4_7_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2005.12.051"},{"key":"e_1_3_4_8_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2005.12.516"},{"key":"e_1_3_4_9_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(10)61381-5"},{"key":"e_1_3_4_10_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM200012283432602"},{"key":"e_1_3_4_11_1","doi-asserted-by":"crossref","unstructured":"International CLL-IPI Working Group. An international prognostic index for patients with chronic lymphocytic leukemia (CLL-IPI): a meta-analysis of individual patient data. Lancet Oncol. 2016;(6):779\u2013790.","DOI":"10.1016\/S1470-2045(16)30029-8"},{"key":"e_1_3_4_12_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V94.6.1848"},{"key":"e_1_3_4_13_1","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdv303"},{"key":"e_1_3_4_14_1","doi-asserted-by":"publisher","DOI":"10.6004\/jnccn.2019.0002"},{"key":"e_1_3_4_15_1","doi-asserted-by":"publisher","DOI":"10.1002\/ajh.24707"},{"key":"e_1_3_4_16_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2017-09-806398"},{"key":"e_1_3_4_17_1","doi-asserted-by":"publisher","DOI":"10.2217\/fon.15.95"},{"key":"e_1_3_4_18_1","article-title":"Ibrutinib versus placebo in patients with asymptomatic, treatment-na\u00efve early stage chronic lymphocytic leukemia (CLL): primary endpoint results of the phase 3 double-blinded randomized CLL12 trial","author":"Langerbeins P","year":"2019","unstructured":"Langerbeins P, Bahlo J, Rhein C, et al. Ibrutinib versus placebo in patients with asymptomatic, treatment-na\u00efve early stage chronic lymphocytic leukemia (CLL): primary endpoint results of the phase 3 double-blinded randomized CLL12 trial. 24th Eur Hematol Aassoc Congr. 2019. Abstract #.","journal-title":"24th Eur Hematol Aassoc Congr"},{"key":"e_1_3_4_19_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(16)30212-1"},{"key":"e_1_3_4_20_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(16)30019-5"},{"key":"e_1_3_4_21_1","article-title":"Initial treatment of CLL: integrating biology and functional status","author":"Jain N","year":"2015","unstructured":"Jain N, O\u2019Brien S. Initial treatment of CLL: integrating biology and functional status. Blood. 2015 Jul;126(4):463\u201370.","journal-title":"Blood"},{"key":"e_1_3_4_22_1","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2001.19.8.2165","article-title":"Rituximab dose-escalation trial in chronic lymphocytic leukemia","volume":"19","author":"O\u2019Brien SM","year":"2001","unstructured":"O\u2019Brien SM, Kantarjian H, Thomas DA, et al. Rituximab dose-escalation trial in chronic lymphocytic leukemia. J Clin Oncol. 2001;19:2165\u20132170.","journal-title":"J Clin Oncol"},{"key":"e_1_3_4_23_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2002-04-1258"},{"key":"e_1_3_4_24_1","doi-asserted-by":"crossref","unstructured":"Cragg MS Walshe CA Ivanov AO et al. The biology of CD20 and its potential as a target for mAb therapy. B cell trophic factors B cell antagon. Curr Dir Autoimmun.\u00a02005;8:140\u201374.","DOI":"10.1159\/000082102"},{"key":"e_1_3_4_25_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2015-06-651125"},{"key":"e_1_3_4_26_1","doi-asserted-by":"publisher","DOI":"10.3109\/10428194.2014.957203"},{"key":"e_1_3_4_27_1","doi-asserted-by":"publisher","DOI":"10.1200\/EDBK_200691"},{"key":"e_1_3_4_28_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(16)30051-1"},{"key":"e_1_3_4_29_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2011.39.2688"},{"key":"e_1_3_4_30_1","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.177.1.362"},{"key":"e_1_3_4_31_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2009-06-225979"},{"key":"e_1_3_4_32_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2009.25.3187"},{"key":"e_1_3_4_33_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1313984"},{"key":"e_1_3_4_34_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2015-09-667675"},{"key":"e_1_3_4_35_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2015-05-647925"},{"key":"e_1_3_4_36_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2017-07-731588"},{"key":"e_1_3_4_37_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1215637"},{"key":"e_1_3_4_38_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(13)70513-8"},{"key":"e_1_3_4_39_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2017-10-810044"},{"key":"e_1_3_4_40_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2014-10-606038"},{"key":"e_1_3_4_41_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2018-99-110847"},{"key":"e_1_3_4_42_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1509388"},{"key":"e_1_3_4_43_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V128.22.234.234"},{"key":"e_1_3_4_44_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2018-120779"},{"key":"e_1_3_4_45_1","first-page":"NEJMoa1812836","article-title":"Ibrutinib regimens versus chemoimmunotherapy in older patients with untreated CLL","author":"Woyach JA","year":"2018","unstructured":"Woyach JA, Ruppert AS, Heerema NA, et al. Ibrutinib regimens versus chemoimmunotherapy in older patients with untreated CLL. N Engl J Med. [Internet]. 2018;NEJMoa1812836. Available from: http:\/\/www.nejm.org\/doi\/10.1056\/NEJMoa1812836","journal-title":"N Engl J Med"},{"key":"e_1_3_4_46_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(18)30788-5"},{"key":"e_1_3_4_47_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V122.21.525.525"},{"key":"e_1_3_4_48_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41375-018-0276-9"},{"key":"e_1_3_4_49_1","first-page":"496LP","article-title":"A multicenter, phase II study of ibrutinib plus FCR (iFCR) as frontline therapy for younger CLL patients","volume":"130","author":"Davids MS","year":"2017","unstructured":"Davids MS, Kim HT, Brander DM, et al. A multicenter, phase II study of ibrutinib plus FCR (iFCR) as frontline therapy for younger CLL patients. Blood. [Internet]. 2017;130:496LP\u2013496. Available from: http:\/\/www.bloodjournal.org\/content\/130\/Suppl_1\/496.abstract","journal-title":"Blood"},{"key":"e_1_3_4_50_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2013-11-538116"},{"key":"e_1_3_4_51_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2018-185"},{"key":"e_1_3_4_52_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(16)30671-4"},{"key":"e_1_3_4_53_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2017-12-820910"},{"key":"e_1_3_4_54_1","article-title":"Toxicities and outcomes of 616 ibrutinib-treated patients in the united states: a real-world analysis","author":"Mato AR","year":"2018","unstructured":"Mato AR, Nabhan C, Thompson MC, et al. Toxicities and outcomes of 616 ibrutinib-treated patients in the united states: a real-world analysis. Haematologica. 2018.","journal-title":"Haematologica"}],"container-title":["Expert Review of Hematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.tandfonline.com\/doi\/pdf\/10.1080\/17474086.2020.1697226","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,4,30]],"date-time":"2024-04-30T09:50:31Z","timestamp":1714470631000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.tandfonline.com\/doi\/full\/10.1080\/17474086.2020.1697226"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,12,10]]},"references-count":52,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2020,1,2]]}},"alternative-id":["10.1080\/17474086.2020.1697226"],"URL":"https:\/\/doi.org\/10.1080\/17474086.2020.1697226","relation":{},"ISSN":["1747-4086","1747-4094"],"issn-type":[{"value":"1747-4086","type":"print"},{"value":"1747-4094","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,12,10]]},"assertion":[{"value":"The publishing and review policy for this title is described in its Aims & Scope.","order":1,"name":"peerreview_statement","label":"Peer Review Statement"},{"value":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=ierr20","URL":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=ierr20","order":2,"name":"aims_and_scope_url","label":"Aim & Scope"},{"value":"2019-04-25","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2019-11-21","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2019-12-10","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}